Artificial Intelligence in Pharmacovigilance Global Market Report 2026
Yahoo Finance ·
The global artificial intelligence in pharmacovigilance market is expanding rapidly, moving from $0.77 billion in 2025 to $0.92 billion in 2026 at a compound annual growth rate of 19.3%. Projections indicate the market will reach $1.88 billion by 2030, driven by a 19.6% CAGR. Industry giants such as Oracle, Microsoft, Google, and IQVIA are accelerating automation to streamline safety workflows and integrate multisource data. Key growth catalysts include rising adverse drug reaction reports, stricter regulations, and enhanced predictive analytics. For instance, the Department of Health Abu Dhabi reported 1,522 adverse drug reaction filings between January and December 2023, representing a 235% surge over historical yearly averages. In response, technology providers are deploying agentic AI solutions, such as RxLogix Systems Inc.'s upgraded PVOne.AI platform launched in May 2026, to automate literature screening, signal management, and regulatory reporting while maintaining vital human oversight.
AI 시장 분석
The global AI in pharmacovigilance market is projected to grow from $92 million in 2026 to $1.88 billion by 2030, at a compound annual growth rate of 19.6%. Accelerated automation by big tech companies like Oracle, Microsoft, and Google is driving market expansion. Investors should pay attention to revenue growth of related companies resulting from the combination of healthcare and AI technologies.
상승 영향
- AI — High growth of 19.6% CAGR in the pharmacovigilance market and accelerated adoption of automation platforms by Oracle, Google, and others directly increase demand for related technologies.
- Biotechnology — Amid surging pharmaceutical adverse event reports and strict regulations, the adoption of AI-based pharmacovigilance systems improves operational efficiency and regulatory compliance for pharmaceutical companies.
DYAX 전담 분석
The adoption of AI in pharmacovigilance directly improves the profitability of related technology companies by reducing the costs of processing vast adverse event reports and accelerating regulatory compliance. According to statistics from the Department of Health Abu Dhabi, adverse reaction reports have surged 235% compared to past averages, creating extremely high demand for automation.
The bullish scenario involves market penetration rising faster than expected due to tightened regulations and advanced big tech platforms, while the bearish scenario entails regulatory risks and cost burdens arising from AI errors. Key monitoring metrics are the number of contract closures by major healthcare IT companies and the achievement of the compound annual growth rate (CAGR).
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 29% · Bearish (Short) 71%
385 participants
Related News
- Tesla Stock Advances As Cybercabs Claim Majority In Texas Robotaxi Registry
- Pre-Market Australian Stocks: Woolworths Beats Q1 Sales Estimates
- Brown & Brown Shares Fall 5% Following Weak Quarterly Financial Results
- Penguin Solutions, Broadcom, FormFactor, Lattice, and AMD Shares Rally on AI Financing News
- Netflix Unveils Leadership Overhaul and Workforce Reduction
- Western Digital, Allegro MicroSystems, Amtech, and Teradyne Shares Surge on Major Tech Financing
